AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Putative NOL1/NOP2/Sun domain family member 5B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q3KNT7

UPID:

NSN5B_HUMAN

Alternative names:

Williams-Beuren syndrome chromosomal region 20B protein

Alternative UPACC:

Q3KNT7; B3KX24; Q52LC6; Q8N728

Background:

The Putative NOL1/NOP2/Sun domain family member 5B, also known as Williams-Beuren syndrome chromosomal region 20B protein, represents a unique protein of interest in the realm of genetic research. Its association with the Williams-Beuren syndrome chromosomal region hints at a complex role in cellular processes and genetic regulation.

Therapeutic significance:

Understanding the role of Putative NOL1/NOP2/Sun domain family member 5B could open doors to potential therapeutic strategies. Its connection to critical chromosomal regions suggests a pivotal role in genetic disorders, making it a prime candidate for targeted drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.